Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Frontiers In Real-World Evidence: US FDA Partners With Syapse To Explore Sources Beyond Electronic Records

Executive Summary

Oncology Center of Excellence will collaborate with the health data company to explore RWE sources for precision medicine.

You may also be interested in...



US FDA's Abernethy 'Cautious' About Real-World Evidence

FDA's principal deputy commissioner, who used to work in the real-world evidence field, said momentum is building, but more successful use cases are needed.

Real-World Evidence: When Is Missing Data Not Really 'Missing'?

The concept of missing data is very different when analyzing real-world evidence compared to a randomized clinical trial.

US FDA Searches For Consistency On Assessment Of Real-World Evidence

As more sponsors begin using RWE, the agency is establishing procedures and training to ensure assessors consistently apply policies.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS140694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel